{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "697148dd",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Google API Key loaded successfully.\n",
      "Loading existing vector store from disk...\n",
      "Vector store loaded successfully!\n",
      "\n",
      "--- Testing the AI Assistant ---\n",
      "\n",
      "Question: What are the main challenges in MASH diagnosis?\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:RetrievalQA] Entering Chain run with input:\n",
      "\u001b[0m{\n",
      "  \"query\": \"What are the main challenges in MASH diagnosis?\"\n",
      "}\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain] Entering Chain run with input:\n",
      "\u001b[0m{\n",
      "  \"question\": \"What are the main challenges in MASH diagnosis?\",\n",
      "  \"context\": \"MASH isn't just a little fat (“gordurinha”) — it's a disease that screams silently, and our biggest challenge is to give it a voice before the damage becomes invisibly irreversible. Just like a microphone turned off during an urgent alert, MASH goes unnoticed by clinicians, pa-tients, and health systems. It hides behind routine tests, advances without symptoms, and is of-ten underestimated as harmless. But behind the label of \\\"fat in the liver\\\", there is a real risk of fibrosis, cirrhosis, cancer and cardiovascular death. To give voice to this disease is to illuminate what is neglected today — it is to recognize the signs, expand access to diagnosis, and trans-form silence into action.  Track Summary          MASH is a silent disease that threatens millions of lives without being heard. The absence of symptoms, the lack of knowledge about diagnostic methods by health professionals, and the lack of public policies make the scenario even more critical. Professionals who accompany\\n\\nsuch as perma-nent scarring of the liver (fibrosis, which in its advanced stages can progress to cirrhosis), liver cancer, and even the need for a liver transplant. It is estimated that 90% of people are not diag-nosed. In addition, people with MASH have a higher risk of developing cardiovascular disease, which is the leading cause of mortality in these cases.[3][8]           The diagnosis of MASH is simple, however, because it is a silent disease and still little known, it usually occurs late – especially because they do not present symptoms in the early stages. Alt-hough there are simple and effective methods, such as FIB-4 — which uses age and common\\n\\nis a silent condition, which means that most patients do not experience symptoms in the early stages. This contributes to 9 out of 10 cases remaining undiagnosed, even among people with risk factors such as obesity and type 2 diabetes.  2. Low medical familiarity with diagnostic methods  Despite the existence of tools such as FIB-4 and hepatic elastography, which allow the evaluation of the liver without the need for biopsy, these methods are still little used in clinical practice. Many health professionals are unaware of these options or do not have access to them.  3. Lack of widely disseminated clinical guidelines The guidelines for screening and management of MASH are not well known by health professionals, which makes it difficult to perform them, especially in primary care. This generates insecurity about when to investigate and how to conduct care.  4. Structural and access barriers\"\n",
      "}\n",
      "\u001b[32;1m\u001b[1;3m[llm/start]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain > llm:GoogleGenerativeAI] Entering LLM run with input:\n",
      "\u001b[0m{\n",
      "  \"prompts\": [\n",
      "    \"Use the following context to answer the question in a detailed and precise manner.\\nIf the answer is not in the context, say \\\"The information is not available in my knowledge base.\\\"\\n\\nContext:\\nMASH isn't just a little fat (“gordurinha”) — it's a disease that screams silently, and our biggest challenge is to give it a voice before the damage becomes invisibly irreversible. Just like a microphone turned off during an urgent alert, MASH goes unnoticed by clinicians, pa-tients, and health systems. It hides behind routine tests, advances without symptoms, and is of-ten underestimated as harmless. But behind the label of \\\"fat in the liver\\\", there is a real risk of fibrosis, cirrhosis, cancer and cardiovascular death. To give voice to this disease is to illuminate what is neglected today — it is to recognize the signs, expand access to diagnosis, and trans-form silence into action.  Track Summary          MASH is a silent disease that threatens millions of lives without being heard. The absence of symptoms, the lack of knowledge about diagnostic methods by health professionals, and the lack of public policies make the scenario even more critical. Professionals who accompany\\n\\nsuch as perma-nent scarring of the liver (fibrosis, which in its advanced stages can progress to cirrhosis), liver cancer, and even the need for a liver transplant. It is estimated that 90% of people are not diag-nosed. In addition, people with MASH have a higher risk of developing cardiovascular disease, which is the leading cause of mortality in these cases.[3][8]           The diagnosis of MASH is simple, however, because it is a silent disease and still little known, it usually occurs late – especially because they do not present symptoms in the early stages. Alt-hough there are simple and effective methods, such as FIB-4 — which uses age and common\\n\\nis a silent condition, which means that most patients do not experience symptoms in the early stages. This contributes to 9 out of 10 cases remaining undiagnosed, even among people with risk factors such as obesity and type 2 diabetes.  2. Low medical familiarity with diagnostic methods  Despite the existence of tools such as FIB-4 and hepatic elastography, which allow the evaluation of the liver without the need for biopsy, these methods are still little used in clinical practice. Many health professionals are unaware of these options or do not have access to them.  3. Lack of widely disseminated clinical guidelines The guidelines for screening and management of MASH are not well known by health professionals, which makes it difficult to perform them, especially in primary care. This generates insecurity about when to investigate and how to conduct care.  4. Structural and access barriers\\n\\nQuestion:\\nWhat are the main challenges in MASH diagnosis?\\n\\nAnswer:\"\n",
      "  ]\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[llm/end]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain > llm:GoogleGenerativeAI] [2.37s] Exiting LLM run with output:\n",
      "\u001b[0m{\n",
      "  \"generations\": [\n",
      "    [\n",
      "      {\n",
      "        \"text\": \"The main challenges in MASH diagnosis are:\\n\\n1. **MASH is a silent disease:**  It lacks symptoms in early stages, leading to late diagnosis and a 90% undiagnosed rate, even in those with risk factors like obesity and type 2 diabetes.\\n\\n2. **Low medical familiarity with diagnostic methods:**  While simple and effective diagnostic tools like FIB-4 and hepatic elastography exist, they are underutilized due to lack of awareness or access among healthcare professionals.\\n\\n3. **Lack of widely disseminated clinical guidelines:**  Insufficient knowledge of screening and management guidelines among healthcare professionals, particularly in primary care, creates uncertainty about when and how to investigate and manage MASH.\\n\\n4. **Structural and access barriers:** The text mentions structural and access barriers but does not elaborate on their specifics.\",\n",
      "        \"generation_info\": {\n",
      "          \"finish_reason\": \"STOP\",\n",
      "          \"model_name\": \"gemini-1.5-flash\",\n",
      "          \"safety_ratings\": [],\n",
      "          \"usage_metadata\": {\n",
      "            \"input_tokens\": 578,\n",
      "            \"output_tokens\": 166,\n",
      "            \"total_tokens\": 744,\n",
      "            \"input_token_details\": {\n",
      "              \"cache_read\": 0\n",
      "            }\n",
      "          }\n",
      "        },\n",
      "        \"type\": \"Generation\"\n",
      "      }\n",
      "    ]\n",
      "  ],\n",
      "  \"llm_output\": null,\n",
      "  \"run\": null,\n",
      "  \"type\": \"LLMResult\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain] [2.38s] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"text\": \"The main challenges in MASH diagnosis are:\\n\\n1. **MASH is a silent disease:**  It lacks symptoms in early stages, leading to late diagnosis and a 90% undiagnosed rate, even in those with risk factors like obesity and type 2 diabetes.\\n\\n2. **Low medical familiarity with diagnostic methods:**  While simple and effective diagnostic tools like FIB-4 and hepatic elastography exist, they are underutilized due to lack of awareness or access among healthcare professionals.\\n\\n3. **Lack of widely disseminated clinical guidelines:**  Insufficient knowledge of screening and management guidelines among healthcare professionals, particularly in primary care, creates uncertainty about when and how to investigate and manage MASH.\\n\\n4. **Structural and access barriers:** The text mentions structural and access barriers but does not elaborate on their specifics.\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain] [2.38s] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"output_text\": \"The main challenges in MASH diagnosis are:\\n\\n1. **MASH is a silent disease:**  It lacks symptoms in early stages, leading to late diagnosis and a 90% undiagnosed rate, even in those with risk factors like obesity and type 2 diabetes.\\n\\n2. **Low medical familiarity with diagnostic methods:**  While simple and effective diagnostic tools like FIB-4 and hepatic elastography exist, they are underutilized due to lack of awareness or access among healthcare professionals.\\n\\n3. **Lack of widely disseminated clinical guidelines:**  Insufficient knowledge of screening and management guidelines among healthcare professionals, particularly in primary care, creates uncertainty about when and how to investigate and manage MASH.\\n\\n4. **Structural and access barriers:** The text mentions structural and access barriers but does not elaborate on their specifics.\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:RetrievalQA] [2.43s] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "Answer: The main challenges in MASH diagnosis are:\n",
      "\n",
      "1. **MASH is a silent disease:**  It lacks symptoms in early stages, leading to late diagnosis and a 90% undiagnosed rate, even in those with risk factors like obesity and type 2 diabetes.\n",
      "\n",
      "2. **Low medical familiarity with diagnostic methods:**  While simple and effective diagnostic tools like FIB-4 and hepatic elastography exist, they are underutilized due to lack of awareness or access among healthcare professionals.\n",
      "\n",
      "3. **Lack of widely disseminated clinical guidelines:**  Insufficient knowledge of screening and management guidelines among healthcare professionals, particularly in primary care, creates uncertainty about when and how to investigate and manage MASH.\n",
      "\n",
      "4. **Structural and access barriers:** The text mentions structural and access barriers but does not elaborate on their specifics.\n",
      "\n",
      "Question: What is the FIB-4 score?\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:RetrievalQA] Entering Chain run with input:\n",
      "\u001b[0m{\n",
      "  \"query\": \"What is the FIB-4 score?\"\n",
      "}\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain] Entering Chain run with input:\n",
      "\u001b[0m{\n",
      "  \"question\": \"What is the FIB-4 score?\",\n",
      "  \"context\": \"Step 1—Calculate the FIB-4 Score\\nIdeally, patients with MASLD should have a FIB-4\\nscore calculated by primary care or endocrinology before\\nreferral to GI/hepatology; however, this will vary from\\nsetting to setting. Nevertheless, it is important to note that\\nFIB-4 is a practical and easy ﬁrst step that needs to be\\ncarried out in the primary care setting. FIB-4 is based on 4\\nsimple data points: age, platelet count, AST, and ALT.\\nTypically, these tests are available and should be performed\\nby primary care providers in individuals at risk for\\nMASLD, such as those with T2D and other risks as\\ndelineated in Table 1. The FIB-4 score is calculated as:\\n(age×AST)/(platelets×square root of ALT) using FIB-4\\ncalculators that can be found online and are often built into\\nelectronic medical record systems (click here for online FIB-\\n4 calculator). A FIB-4 score≥1.3 (≥2.0 for those 65 y and\\nolder) has been determined as the cutoff score as to when an\\n\\nproﬁle should follow different pathways depending on the result of\\nthis test, owing to a potentially high number of individuals in this\\ngroup with unidentiﬁed advancedﬁbrosis.\\n49,52 If FIB-4 is below\\n1.3, these individuals can be assumed to be at low risk of\\nadvanced ﬁbrosis and may be re-assessed every 1-3 years.\\nHowever, despite the high negative predictive value, clinicians\\nshould recognise that FIB-4 will miss around 10% of individuals\\nwith advancedﬁbrosis, and it has not been formally demonstrated\\nthat repeating FIB-4 over time is effective in picking up the\\nremaining individuals. If FIB-4 is>1.3 (or>2.0 in individuals aged\\n>65), the risk for advancedﬁbrosis is increased. However, due to\\nthe low predictive value, the high number of false positive results\\nmay create a high subsequent testing burden. Thus, two options\\nare recommended in individuals with FIB-4 scores between 1.3\\nand 2.67, depending on medical history, clinical context, and local\\n\\n4 calculator). A FIB-4 score≥1.3 (≥2.0 for those 65 y and\\nolder) has been determined as the cutoff score as to when an\\nindividual with MASLD requires further evaluation. At a\\nlower cutoff value of < 1.3, the FIB-4 has a negative\\npredictive value of ∼95% meaning that the presence of\\nTABLE 3. AUDIT-C Scores and Phosphatidyl Ethanol (PEth)\\nThresholds\\nAUDIT-C Scores\\nQ1. How often did you have a drink containing alcohol in the past\\nyear?\\nAnswer Points\\nNever 0\\nMonthly or less 1\\n2-4 times a month 2\\n2-3 times a week 3\\n4 or more times a week 4\\nQ2: How many drinks did you have on a typical day when you were\\ndrinking in the past year?\\nAnswer Points\\nNo, I do not drink 0\\n1o r2 0\\n3o r4 1\\n5o r6 2\\n7o r9 3\\n10 or more 4\\nQ3: How often did you have 6 or more drinks on 1 occasion in the\\npast year?\\nAnswer Points\\nNever 0\\nLess than monthly 1\\nMonthly 2\\nWeekly 3\\nDaily or almost daily 4\\nAUDIT-C interpretation Total score\\nSigniﬁcant alcohol consumption level that\\nis affecting health and safety\\n≥4 for men≥3 for\"\n",
      "}\n",
      "\u001b[32;1m\u001b[1;3m[llm/start]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain > llm:GoogleGenerativeAI] Entering LLM run with input:\n",
      "\u001b[0m{\n",
      "  \"prompts\": [\n",
      "    \"Use the following context to answer the question in a detailed and precise manner.\\nIf the answer is not in the context, say \\\"The information is not available in my knowledge base.\\\"\\n\\nContext:\\nStep 1—Calculate the FIB-4 Score\\nIdeally, patients with MASLD should have a FIB-4\\nscore calculated by primary care or endocrinology before\\nreferral to GI/hepatology; however, this will vary from\\nsetting to setting. Nevertheless, it is important to note that\\nFIB-4 is a practical and easy ﬁrst step that needs to be\\ncarried out in the primary care setting. FIB-4 is based on 4\\nsimple data points: age, platelet count, AST, and ALT.\\nTypically, these tests are available and should be performed\\nby primary care providers in individuals at risk for\\nMASLD, such as those with T2D and other risks as\\ndelineated in Table 1. The FIB-4 score is calculated as:\\n(age×AST)/(platelets×square root of ALT) using FIB-4\\ncalculators that can be found online and are often built into\\nelectronic medical record systems (click here for online FIB-\\n4 calculator). A FIB-4 score≥1.3 (≥2.0 for those 65 y and\\nolder) has been determined as the cutoff score as to when an\\n\\nproﬁle should follow different pathways depending on the result of\\nthis test, owing to a potentially high number of individuals in this\\ngroup with unidentiﬁed advancedﬁbrosis.\\n49,52 If FIB-4 is below\\n1.3, these individuals can be assumed to be at low risk of\\nadvanced ﬁbrosis and may be re-assessed every 1-3 years.\\nHowever, despite the high negative predictive value, clinicians\\nshould recognise that FIB-4 will miss around 10% of individuals\\nwith advancedﬁbrosis, and it has not been formally demonstrated\\nthat repeating FIB-4 over time is effective in picking up the\\nremaining individuals. If FIB-4 is>1.3 (or>2.0 in individuals aged\\n>65), the risk for advancedﬁbrosis is increased. However, due to\\nthe low predictive value, the high number of false positive results\\nmay create a high subsequent testing burden. Thus, two options\\nare recommended in individuals with FIB-4 scores between 1.3\\nand 2.67, depending on medical history, clinical context, and local\\n\\n4 calculator). A FIB-4 score≥1.3 (≥2.0 for those 65 y and\\nolder) has been determined as the cutoff score as to when an\\nindividual with MASLD requires further evaluation. At a\\nlower cutoff value of < 1.3, the FIB-4 has a negative\\npredictive value of ∼95% meaning that the presence of\\nTABLE 3. AUDIT-C Scores and Phosphatidyl Ethanol (PEth)\\nThresholds\\nAUDIT-C Scores\\nQ1. How often did you have a drink containing alcohol in the past\\nyear?\\nAnswer Points\\nNever 0\\nMonthly or less 1\\n2-4 times a month 2\\n2-3 times a week 3\\n4 or more times a week 4\\nQ2: How many drinks did you have on a typical day when you were\\ndrinking in the past year?\\nAnswer Points\\nNo, I do not drink 0\\n1o r2 0\\n3o r4 1\\n5o r6 2\\n7o r9 3\\n10 or more 4\\nQ3: How often did you have 6 or more drinks on 1 occasion in the\\npast year?\\nAnswer Points\\nNever 0\\nLess than monthly 1\\nMonthly 2\\nWeekly 3\\nDaily or almost daily 4\\nAUDIT-C interpretation Total score\\nSigniﬁcant alcohol consumption level that\\nis affecting health and safety\\n≥4 for men≥3 for\\n\\nQuestion:\\nWhat is the FIB-4 score?\\n\\nAnswer:\"\n",
      "  ]\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[llm/end]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain > llm:GoogleGenerativeAI] [954ms] Exiting LLM run with output:\n",
      "\u001b[0m{\n",
      "  \"generations\": [\n",
      "    [\n",
      "      {\n",
      "        \"text\": \"The FIB-4 score is calculated as (age × AST) / (platelets × square root of ALT).  A score ≥1.3 (≥2.0 for those 65 years and older) indicates a need for further evaluation for MASLD.  A score <1.3 suggests a low risk of advanced fibrosis.\",\n",
      "        \"generation_info\": {\n",
      "          \"finish_reason\": \"STOP\",\n",
      "          \"model_name\": \"gemini-1.5-flash\",\n",
      "          \"safety_ratings\": [],\n",
      "          \"usage_metadata\": {\n",
      "            \"input_tokens\": 862,\n",
      "            \"output_tokens\": 70,\n",
      "            \"total_tokens\": 932,\n",
      "            \"input_token_details\": {\n",
      "              \"cache_read\": 0\n",
      "            }\n",
      "          }\n",
      "        },\n",
      "        \"type\": \"Generation\"\n",
      "      }\n",
      "    ]\n",
      "  ],\n",
      "  \"llm_output\": null,\n",
      "  \"run\": null,\n",
      "  \"type\": \"LLMResult\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain] [956ms] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"text\": \"The FIB-4 score is calculated as (age × AST) / (platelets × square root of ALT).  A score ≥1.3 (≥2.0 for those 65 years and older) indicates a need for further evaluation for MASLD.  A score <1.3 suggests a low risk of advanced fibrosis.\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain] [958ms] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"output_text\": \"The FIB-4 score is calculated as (age × AST) / (platelets × square root of ALT).  A score ≥1.3 (≥2.0 for those 65 years and older) indicates a need for further evaluation for MASLD.  A score <1.3 suggests a low risk of advanced fibrosis.\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:RetrievalQA] [1.02s] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "Answer: The FIB-4 score is calculated as (age × AST) / (platelets × square root of ALT).  A score ≥1.3 (≥2.0 for those 65 years and older) indicates a need for further evaluation for MASLD.  A score <1.3 suggests a low risk of advanced fibrosis.\n",
      "\n",
      "Question: What is the prevalence of MASH in Latin America?\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:RetrievalQA] Entering Chain run with input:\n",
      "\u001b[0m{\n",
      "  \"query\": \"What is the prevalence of MASH in Latin America?\"\n",
      "}\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain] Entering Chain run with input:\n",
      "\u001b[0m[inputs]\n",
      "\u001b[32;1m\u001b[1;3m[chain/start]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain] Entering Chain run with input:\n",
      "\u001b[0m{\n",
      "  \"question\": \"What is the prevalence of MASH in Latin America?\",\n",
      "  \"context\": \"laboratory test results — and liver elastography — which evaluates liver stiffness — these tests are still little known in clinical practice.[10] Liver biopsy, on the other hand, despite being the gold standard for diagnosis, is highly invasive and uncomfortable, in addition to having its own limita-tions in terms of accuracy, which limits its application on a large scale.  Prevalence of MASH           Latin America faces an alarming prevalence of liver diseases associated with metabolic dys-function. Liver fat affects 44% of the population [4], exceeding the global average of 23.67% [5], while 7.1% evolve to MASH — also above the world average of 5%.[4]          It is estimated that about 32 million people live with MASH in Latin America. [1][2] One-third of people with obesity already have the condition [1][2], and approximately 65 percent of people with type 2 diabetes have fat accumulation in the liver [5][6] —about 40 percent of whom have already developed significant fibrosis\\n\\n(resmetirom) had lower levels of agreement and generated\\nsome important comments, triggering the fourth-round Delphi\\nsurvey, which included 8 statements ( Supplementary\\nTable 12). All these statements were agreed on by a super-\\nmajority, with few comments (Supplementary Table 13).\\nSummary of MASLD Document Review and\\nConsensus\\nEpidemiology and progression of MASLD. State-\\nments and items included in this section did not require\\ninclusion in the Delphi process. Most of the guidelines (47 of\\n61, 78%) provided some epidemiology information, with\\nmore recent publications providing more updated epide-\\nmiology information. In the early guidelines, the prevalence\\nof MASLD in the adult global population was cited to be\\napproximately 25%. Guidelines that cited meta-analysis\\ndata estimated the global prevalence of MASLD to be\\napproximately 38%.\\n2 The global prevalence of MASH was\\nmentioned in a quarter of the guidelines (n ¼ 15), and\\nestimated to be 3% to 5%, with the most recent guidelines\\n\\n2 The global prevalence of MASH was\\nmentioned in a quarter of the guidelines (n ¼ 15), and\\nestimated to be 3% to 5%, with the most recent guidelines\\nestimating MASH prevalence to be 5.27%. (5%–7%).\\n1–5,7\\nTable 2 provides prevalence, incidence, and all-cause and\\ncause-speciﬁc mortality values reported by the guidelines.\\nAlthough these are average values for different countries or\\nregions, differences exist within regions. For example, in the\\nguideline from Indian National Association for Study of the\\nLiver, the prevalence of MASLD was estimated to be 38% in\\nadults and 35% in children, with signi ﬁcant differences\\nbetween the urban and rural areas of India.\\n11\\nScreening for MASLD, including alcohol con-\\nsumption. Based on the initial review of guidelines,\\nseveral areas related to the screening for MASLD required\\nsubsequent Delphi processes. After 4 steps, there was\\nconsensus to investigate and stratify for high-risk MASLD in\\npatients with any 1 of the following:\\n1. Presence of T2D.\"\n",
      "}\n",
      "\u001b[32;1m\u001b[1;3m[llm/start]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain > llm:GoogleGenerativeAI] Entering LLM run with input:\n",
      "\u001b[0m{\n",
      "  \"prompts\": [\n",
      "    \"Use the following context to answer the question in a detailed and precise manner.\\nIf the answer is not in the context, say \\\"The information is not available in my knowledge base.\\\"\\n\\nContext:\\nlaboratory test results — and liver elastography — which evaluates liver stiffness — these tests are still little known in clinical practice.[10] Liver biopsy, on the other hand, despite being the gold standard for diagnosis, is highly invasive and uncomfortable, in addition to having its own limita-tions in terms of accuracy, which limits its application on a large scale.  Prevalence of MASH           Latin America faces an alarming prevalence of liver diseases associated with metabolic dys-function. Liver fat affects 44% of the population [4], exceeding the global average of 23.67% [5], while 7.1% evolve to MASH — also above the world average of 5%.[4]          It is estimated that about 32 million people live with MASH in Latin America. [1][2] One-third of people with obesity already have the condition [1][2], and approximately 65 percent of people with type 2 diabetes have fat accumulation in the liver [5][6] —about 40 percent of whom have already developed significant fibrosis\\n\\n(resmetirom) had lower levels of agreement and generated\\nsome important comments, triggering the fourth-round Delphi\\nsurvey, which included 8 statements ( Supplementary\\nTable 12). All these statements were agreed on by a super-\\nmajority, with few comments (Supplementary Table 13).\\nSummary of MASLD Document Review and\\nConsensus\\nEpidemiology and progression of MASLD. State-\\nments and items included in this section did not require\\ninclusion in the Delphi process. Most of the guidelines (47 of\\n61, 78%) provided some epidemiology information, with\\nmore recent publications providing more updated epide-\\nmiology information. In the early guidelines, the prevalence\\nof MASLD in the adult global population was cited to be\\napproximately 25%. Guidelines that cited meta-analysis\\ndata estimated the global prevalence of MASLD to be\\napproximately 38%.\\n2 The global prevalence of MASH was\\nmentioned in a quarter of the guidelines (n ¼ 15), and\\nestimated to be 3% to 5%, with the most recent guidelines\\n\\n2 The global prevalence of MASH was\\nmentioned in a quarter of the guidelines (n ¼ 15), and\\nestimated to be 3% to 5%, with the most recent guidelines\\nestimating MASH prevalence to be 5.27%. (5%–7%).\\n1–5,7\\nTable 2 provides prevalence, incidence, and all-cause and\\ncause-speciﬁc mortality values reported by the guidelines.\\nAlthough these are average values for different countries or\\nregions, differences exist within regions. For example, in the\\nguideline from Indian National Association for Study of the\\nLiver, the prevalence of MASLD was estimated to be 38% in\\nadults and 35% in children, with signi ﬁcant differences\\nbetween the urban and rural areas of India.\\n11\\nScreening for MASLD, including alcohol con-\\nsumption. Based on the initial review of guidelines,\\nseveral areas related to the screening for MASLD required\\nsubsequent Delphi processes. After 4 steps, there was\\nconsensus to investigate and stratify for high-risk MASLD in\\npatients with any 1 of the following:\\n1. Presence of T2D.\\n\\nQuestion:\\nWhat is the prevalence of MASH in Latin America?\\n\\nAnswer:\"\n",
      "  ]\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[llm/end]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain > llm:GoogleGenerativeAI] [719ms] Exiting LLM run with output:\n",
      "\u001b[0m{\n",
      "  \"generations\": [\n",
      "    [\n",
      "      {\n",
      "        \"text\": \"The prevalence of MASH in Latin America is estimated to be 7.1%, exceeding the world average of 5%.  Approximately 32 million people in Latin America live with MASH.\",\n",
      "        \"generation_info\": {\n",
      "          \"finish_reason\": \"STOP\",\n",
      "          \"model_name\": \"gemini-1.5-flash\",\n",
      "          \"safety_ratings\": [],\n",
      "          \"usage_metadata\": {\n",
      "            \"input_tokens\": 763,\n",
      "            \"output_tokens\": 41,\n",
      "            \"total_tokens\": 804,\n",
      "            \"input_token_details\": {\n",
      "              \"cache_read\": 0\n",
      "            }\n",
      "          }\n",
      "        },\n",
      "        \"type\": \"Generation\"\n",
      "      }\n",
      "    ]\n",
      "  ],\n",
      "  \"llm_output\": null,\n",
      "  \"run\": null,\n",
      "  \"type\": \"LLMResult\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain > chain:LLMChain] [721ms] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"text\": \"The prevalence of MASH in Latin America is estimated to be 7.1%, exceeding the world average of 5%.  Approximately 32 million people in Latin America live with MASH.\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:RetrievalQA > chain:StuffDocumentsChain] [722ms] Exiting Chain run with output:\n",
      "\u001b[0m{\n",
      "  \"output_text\": \"The prevalence of MASH in Latin America is estimated to be 7.1%, exceeding the world average of 5%.  Approximately 32 million people in Latin America live with MASH.\"\n",
      "}\n",
      "\u001b[36;1m\u001b[1;3m[chain/end]\u001b[0m \u001b[1m[chain:RetrievalQA] [787ms] Exiting Chain run with output:\n",
      "\u001b[0m[outputs]\n",
      "Answer: The prevalence of MASH in Latin America is estimated to be 7.1%, exceeding the world average of 5%.  Approximately 32 million people in Latin America live with MASH.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# --- STEP ZERO: NETWORK CONFIGURATION FOR WSL ---\n",
    "import os\n",
    "os.environ[\"GRPC_DNS_RESOLVER\"] = \"native\"\n",
    "# --- END OF NETWORK CONFIGURATION ---\n",
    "\n",
    "from dotenv import load_dotenv\n",
    "import time\n",
    "import langchain\n",
    "\n",
    "# Load environment variables from the .env file\n",
    "load_dotenv()\n",
    "\n",
    "# Check if the Google API key was loaded\n",
    "if 'GOOGLE_API_KEY' not in os.environ:\n",
    "    print(\"Error: Google API Key not found. Check your .env file.\")\n",
    "else:\n",
    "    print(\"Google API Key loaded successfully.\")\n",
    "\n",
    "# --- Imports for AI libraries ---\n",
    "from langchain_community.document_loaders import DirectoryLoader, PyPDFLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_community.embeddings import HuggingFaceEmbeddings\n",
    "from langchain_community.vectorstores import FAISS\n",
    "from langchain_google_genai import GoogleGenerativeAI\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.prompts import PromptTemplate\n",
    "\n",
    "# --- STEP 3.3.3: CREATE OR LOAD THE VECTOR STORE ---\n",
    "# Define the path for the saved FAISS index\n",
    "FAISS_INDEX_PATH = \"faiss_index\"\n",
    "\n",
    "# Define the embedding model to be used.\n",
    "model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "model_kwargs = {'device': 'cpu'} # Use 'cuda' if you have a configured GPU\n",
    "encode_kwargs = {'normalize_embeddings': False}\n",
    "embeddings = HuggingFaceEmbeddings(\n",
    "    model_name=model_name,\n",
    "    model_kwargs=model_kwargs,\n",
    "    encode_kwargs=encode_kwargs\n",
    ")\n",
    "\n",
    "# Check if the vector store already exists\n",
    "if os.path.exists(FAISS_INDEX_PATH):\n",
    "    print(\"Loading existing vector store from disk...\")\n",
    "    # allow_dangerous_deserialization is needed for loading local FAISS indexes\n",
    "    vectorstore = FAISS.load_local(FAISS_INDEX_PATH, embeddings, allow_dangerous_deserialization=True)\n",
    "    print(\"Vector store loaded successfully!\")\n",
    "else:\n",
    "    print(\"No existing vector store found. Creating a new one...\")\n",
    "    # --- STEP 3.3.1: LOAD THE KNOWLEDGE BASE ---\n",
    "    loader = DirectoryLoader('./knowledge_base/', glob=\"./*.pdf\", loader_cls=PyPDFLoader)\n",
    "    documents = loader.load()\n",
    "    print(f\"Total documents loaded: {len(documents)}\")\n",
    "\n",
    "    # --- STEP 3.3.2: SPLIT DOCUMENTS INTO CHUNKS ---\n",
    "    text_splitter = RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=150)\n",
    "    texts = text_splitter.split_documents(documents)\n",
    "    print(f\"Total text chunks created: {len(texts)}\")\n",
    "\n",
    "    # Create the FAISS vector store from the text chunks and the embedding model.\n",
    "    print(\"\\nCreating embeddings and vector store... This might take a moment.\")\n",
    "    vectorstore = FAISS.from_documents(texts, embeddings)\n",
    "    print(\"Vector store created successfully!\")\n",
    "\n",
    "    # Save the vector store to disk for future use\n",
    "    vectorstore.save_local(FAISS_INDEX_PATH)\n",
    "    print(f\"Vector store saved to disk at: {FAISS_INDEX_PATH}\")\n",
    "\n",
    "\n",
    "# --- STEP 3.3.4: CONFIGURE THE LLM AND THE RETRIEVAL CHAIN ---\n",
    "# Configure the LLM that will be used to generate answers\n",
    "llm = GoogleGenerativeAI(model=\"gemini-1.5-flash\", temperature=0.3) # <--- FINAL CORRECTED MODEL NAME\n",
    "\n",
    "# Create a prompt template to instruct the LLM on how to behave\n",
    "prompt_template = \"\"\"\n",
    "Use the following context to answer the question in a detailed and precise manner.\n",
    "If the answer is not in the context, say \"The information is not available in my knowledge base.\"\n",
    "\n",
    "Context:\n",
    "{context}\n",
    "\n",
    "Question:\n",
    "{question}\n",
    "\n",
    "Answer:\n",
    "\"\"\"\n",
    "PROMPT = PromptTemplate(template=prompt_template, input_variables=[\"context\", \"question\"])\n",
    "\n",
    "# Create the Retrieval Question-Answering chain\n",
    "qa_chain = RetrievalQA.from_chain_type(\n",
    "    llm=llm,\n",
    "    chain_type=\"stuff\",\n",
    "    retriever=vectorstore.as_retriever(search_kwargs={\"k\": 3}), # Retrieve the 3 most relevant chunks\n",
    "    return_source_documents=True,\n",
    "    chain_type_kwargs={\"prompt\": PROMPT}\n",
    ")\n",
    "\n",
    "# --- STEP 3.3.5: TESTING THE SYSTEM ---\n",
    "print(\"\\n--- Testing the AI Assistant ---\")\n",
    "\n",
    "# Now you can ask questions directly without debug mode for a cleaner output\n",
    "question1 = \"What are the main challenges in MASH diagnosis?\"\n",
    "print(f\"\\nQuestion: {question1}\")\n",
    "response1 = qa_chain.invoke({\"query\": question1})\n",
    "print(f\"Answer: {response1['result']}\\n\")\n",
    "\n",
    "question2 = \"What is the FIB-4 score?\"\n",
    "print(f\"Question: {question2}\")\n",
    "response2 = qa_chain.invoke({\"query\": question2})\n",
    "print(f\"Answer: {response2['result']}\\n\")\n",
    "\n",
    "question3 = \"What is the prevalence of MASH in Latin America?\"\n",
    "print(f\"Question: {question3}\")\n",
    "response3 = qa_chain.invoke({\"query\": question3})\n",
    "print(f\"Answer: {response3['result']}\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "06b44160-954f-4e9f-b5c8-3f4a18b4cc62",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.8"
  },
  "toc": {
   "base_numbering": 1,
   "nav_menu": {},
   "number_sections": true,
   "sideBar": true,
   "skip_h1_title": false,
   "title_cell": "Table of Contents",
   "title_sidebar": "Contents",
   "toc_cell": false,
   "toc_position": {},
   "toc_section_display": true,
   "toc_window_display": false
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
